Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems
On Sept. 3, 2020, Roche announced that the cobas SARS-CoV-2 & Influenza A/B Test for use on the…
-
-
NIH to boost national COVID-19 testing capacity
On Sept. 2, 2020, the National Institutes of Health (NIH) announced $129.3 million in scale-up and manufacturing support…
-
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the…
-
US Army uniquely poised to battle global pandemic
On Sept. 2, 2020, U.S. Army Medical Research and Development Command continues to combat the virus on several…
-
Broad Institute provided COVID-19 screening for students, faculty and staff at more than 100 colleges and universities
On Sept. 2, 2020, Broad Institute of MIT and Harvard announced it had partnered with 108 public and…
-
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…
-
Janssen discontinued Pimodivir influenza development program
On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a…
-
OPKO Health’s BioReference Laboratories announced New York City Schools COVID-19 testing program
On Sept. 2, 2020, BioReference Laboratories, an OPKO Health company, began testing New York City principals, teachers and…
-
Aegis Sciences awarded $66 million NIH grant to rapidly expand COVID-19 test capacity
On Sept. 2, 2020, Aegis Sciences announced that it had been selected to participate in the National Institutes…
-
PathGroup selected by NIH to become RADx program ‘mega-lab’ for COVID-19 testing
On Sept. 2, 2020, PathGroup announced the award of a funding grant from the National Institutes of Health…
-
Biotechnology | Diagnostics | HIV | Infectious Disease | Non-Profit Research | Organ Transplant | Therapeutics
UT Southwestern performed first HIV-positive-to-HIV-positive organ transplant in Texas
On Sept. 2, 2020, less than three weeks after getting on an organ transplant list for HIV-positive patients,…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | IRB | NIH
Sonic Healthcare expand COVID-19 testing capacity in US in collaboration with NIH RADx Initiative
On Sept. 2, 2020, Sonic Healthcare USA was awarded a contract from the National Institutes of Health (NIH)…
-
NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test
On Sept. 2, 2020, MicroGEM announced it had been awarded up to $40.9 million by the National Institutes…
-
Custom face shields aimed to block droplets, tackled COVID-19 for football players
On Sept. 2, 2020, researchers from the Virginia Tech Helmet Lab announced the development of a football helmet…
-
Aegis Life launched to fight COVID-19 via DNA vaccines and therapeutics enabled by Fusogenix delivery technology
On Sept. 1, 2020, Entos Pharmaceuticals announce the launch of its San Diego-based spinout company Aegis Life, dedicated…
-
Roche received FDA approval for first HIV-1/HIV-2 Qualitative test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
On Sept. 1, 2020, Roche announced FDA approval for the cobas HIV-1/HIV-2 Qualitative Test for use on the…
-
NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries
On Sept. 1, 2020, the National Institutes of Health announced that it had launched a study to track…
-
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
-
MediciNova announced development progress on intranasal formulation of SARS-CoV-2 vaccine for COVID-19
On Sept. 1, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
Arcadia Biosciences acquired proprietary hemp varieties with acquisition of Industrial Seed Innovations
On Sept. 1, 2020, Arcadia Biosciences announced it had completed the purchase of Oregon-based Industrial Seed Innovations (ISI)…
-
Amyris scaled first fermentation-based cannabinoid
On Sept. 1, 2020, Amyris announced that it had successfully scaled up the commercial production of Cannabigerol (CBG)…
-
Lenzilumab COVID-19 case-control study published in Mayo Clinic Proceedings Journal
On Sept. 1, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80%…
-
Sanofi updated Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the US
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
-
HDT BIO received NIH contract to advance novel RNA/LION COVID-19 vaccine into clinical trials
On Sept. 1, 2020, HDT Bio received a notice of award from the National Institute of Allergy and…
-
National Wastewater Surveillance System launched to detect antimicrobial resistance and COVID-19
In September 2020, the Centers for Disease Control and Prevention (CDC) announced the launch of the National Wastewater…
-
Phase 3 clinical testing in the US of AstraZeneca COVID-19 vaccine candidate began
On Aug. 31, 2020, a multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222…
-
Biotechnology | Diagnostics | Disease | NIH
New gene associated with reduced risk for cirrhosis
On Aug. 31, 2020, An international team of scientists supported by the National Institute on Alcohol Abuse and…
-
Vir Biotechnology and GSK started phase 2/3 study of COVID-19 antibody treatment
On Aug. 31, 2020, Vir Biotechnology and GlaxoSmithKline announced that the first patient was dosed in a phase…
-
Novavax and Canada reached agreement to acquire Novavax COVID-19 vaccine
On Aug. 31, 2020, Novavax announced it had reached an agreement in principle with the Government of Canada…
-
Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
